P2D7KK

P2D7KK is a fully human anti-IL-1β monoclonal antibody (IgG1) developed through phage display technology and engineered to be germline-like. It was derived from the affinity-matured clone P2D7 by introducing germline mutations. The antibody demonstrates high affinity binding to IL-1β and potently neutralizes human, mouse, and rhesus macaque IL-1β through a receptor binding site blockade mechanism. P2D7KK binds to IL-1β and directly competes with IL-1 receptor type I (IL-1RI) binding, preventing IL-1β signaling. This mechanism is similar to canakinumab but targets a distinct, non-overlapping epitope on IL-1β. The antibody shows 11-fold higher in vitro neutralization potency compared to canakinumab (IC50 of 5 pM for human IL-1β, 132 pM for mouse IL-1β, and 4 pM for rhesus monkey IL-1β). Due to its human IgG structure, P2D7KK has an extended half-life of approximately 2 weeks, offering potential advantages over shorter-acting IL-1 inhibitors like anakinra. The cross-reactivity with mouse and monkey IL-1β enables preclinical testing in animal models. Developed by A*STAR researchers in Singapore, P2D7KK has demonstrated efficacy in multiple preclinical inflammatory disease models including collagen antibody-induced arthritis, monosodium urate-induced peritonitis (gout model), multiple myeloma, and chronic kidney disease with associated anemia.

Other names

P2D7P-2D7P 2D7